Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Who dumped who?

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Jan 16, 2023 10:04am

139 Views

Post# 35225429

RE:Who dumped who?

navajojoe wrote: So R&F, after not buying any product for months, is out of the picture. Good riddnace.

But this is curious:
"Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will now be the sole licensee of the technology as per the agreement signed June 2022."

So Abbvie demanded that they be the "sole licensee"? Or is this more cover bs for yet another failure by management? Enquiring minds want to know.

Well at least it is worth a cent and a half to the good in early trading. That's a plus.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China